Rozex

How to order Rozex

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Rozex on Prescriptsy

Rozex is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Rozex is a topical treatment containing metronidazole 0.75% w/w, available as a cream or gel.

It is licensed for the treatment of inflammatory papules, pustules, and erythema of rosacea (also known as acne rosacea).

Rosacea is a common chronic skin condition that predominantly affects the central face, causing persistent redness, visible blood vessels, and inflammatory spots.

Rozex works by reducing inflammation through anti-inflammatory and antimicrobial mechanisms and is one of the most established topical treatments for rosacea in clinical use.

It is a prescription-only medicine (POM) in the United Kingdom, manufactured by Galderma.

Rosacea affects approximately 1 in 10 people in the United Kingdom, though many cases remain undiagnosed.

It is more common in people with fair skin and typically presents between the ages of 30 and 50.

The condition follows a relapsing and remitting course, with flares triggered by factors including sun exposure, temperature extremes, alcohol, spicy food, stress, and hot drinks.

Although rosacea is not life-threatening, it can cause significant psychological distress, affecting self-esteem, social interactions, and quality of life.

Effective treatment can substantially improve symptoms and reduce the frequency and severity of flares.

This page provides a comprehensive clinical guide to Rozex, covering how it works, how to use it, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about Rozex

Before reading further, please note these essential safety points.

• Rozex is for external use on the face only. Avoid contact with the eyes, mouth, and mucous membranes.
• Sun protection is essential during treatment. Use a broad-spectrum SPF 30 or higher sunscreen daily, as both metronidazole and rosacea itself are affected by UV exposure.
• Full clinical benefit may take 8 to 12 weeks. Continue treatment as directed even if improvement seems slow.
• Rozex controls symptoms but does not cure rosacea. Symptoms may return after stopping treatment.
• If your condition worsens or you develop new symptoms (such as eye involvement), consult your prescriber.

Understanding rosacea

Rosacea is a chronic inflammatory skin disorder that primarily affects the convexities of the central face (cheeks, nose, chin, forehead, and glabella).

It is classified into several subtypes, although these are increasingly viewed as components of a single disease spectrum.

Erythematotelangiectatic rosacea is characterised by persistent central facial erythema (redness) and telangiectasia (visible blood vessels).

Papulopustular rosacea involves inflammatory papules and pustules superimposed on background erythema, resembling acne but without comedones (blackheads and whiteheads).

Phymatous rosacea involves skin thickening, most notably rhinophyma (enlargement and distortion of the nose).

Ocular rosacea affects the eyes, causing symptoms such as dryness, grittiness, burning, lid margin telangiectasia, and blepharitis.

The pathophysiology of rosacea involves dysregulation of the innate immune system, neurovascular dysfunction, and altered skin barrier function.

Key molecular mediators include cathelicidin (LL-37), kallikrein-related peptidases, matrix metalloproteinases, and reactive oxygen species.

Demodex folliculorum mites, which are found in higher density on rosacea-affected skin, may trigger innate immune activation and contribute to inflammation.

Neurovascular dysregulation underlies the flushing and persistent erythema, while chronic inflammation drives papule and pustule formation.

Understanding these mechanisms explains why treatments for rosacea target different aspects of the disease process.

How Rozex works

Metronidazole is a nitroimidazole compound with well-established antimicrobial properties when used systemically. However, its mechanism of action in rosacea is primarily anti-inflammatory rather than antimicrobial.

The exact mechanisms are not fully elucidated, but research has identified several contributing effects.

Metronidazole scavenges reactive oxygen species (ROS) produced by activated neutrophils, reducing oxidative damage to the skin.

It inhibits neutrophil chemotaxis and migration, thereby reducing the inflammatory cell infiltrate in rosacea lesions.

It may also have direct anti-inflammatory effects on the innate immune response, modulating the production of pro-inflammatory cytokines.

Additionally, metronidazole may reduce the density of Demodex folliculorum mites on the skin.

Although the role of Demodex in rosacea is not fully established, studies have shown a correlation between Demodex density and rosacea severity, and treatments that reduce mite numbers (including metronidazole and ivermectin) improve symptoms.

The antimicrobial activity of metronidazole against Demodex-associated bacteria (Bacillus oleronius) may also contribute to its therapeutic effect.

Topical metronidazole has minimal systemic absorption.

Studies show that less than 1% of the applied dose is recovered in the serum, and steady-state plasma concentrations after twice-daily topical application are approximately 100 times lower than those achieved with standard oral dosing.

This means that systemic side effects associated with oral metronidazole (gastrointestinal disturbance, metallic taste, peripheral neuropathy, disulfiram-like reaction with alcohol) are not clinically relevant with Rozex.

Clinical evidence for Rozex

Topical metronidazole has been used for rosacea since the 1980s and is one of the most extensively studied topical treatments for the condition.

Multiple randomised controlled trials have demonstrated that metronidazole 0.75% (applied once or twice daily) is significantly more effective than vehicle (placebo) in reducing inflammatory lesion counts (papules and pustules) and erythema.

In typical trials, topical metronidazole reduces inflammatory lesion counts by approximately 50% to 65% over 8 to 12 weeks, compared with 20% to 35% with vehicle alone.

Long-term studies have shown that topical metronidazole maintains its efficacy over 6 to 12 months of continuous use and is well tolerated with prolonged application.

Relapse rates after stopping treatment are high (rosacea is chronic), which supports the rationale for intermittent or maintenance therapy.

The British Association of Dermatologists (BAD) guidelines on the management of rosacea recommend topical metronidazole as a first-line treatment for mild to moderate papulopustular rosacea.

NICE CKS on rosacea similarly recommends topical metronidazole or topical ivermectin as initial pharmacological treatment for papulopustular rosacea.

Rozex compared with other rosacea treatments

Several topical treatments are available for papulopustular rosacea in the UK. Ivermectin 1% cream (Soolantra) is a newer alternative that targets Demodex mites and has anti-inflammatory properties.

Head-to-head trials have shown that ivermectin 1% cream is superior to metronidazole 0.75% in reducing inflammatory lesion counts over 16 weeks, although both are effective.

NICE CKS considers both to be appropriate first-line options, with the choice influenced by availability, cost, and patient preference.

Azelaic acid 15% gel (Finacea) is another topical option that reduces papules, pustules, and erythema through anti-inflammatory and antimicrobial mechanisms.

Topical brimonidine 0.33% gel (Mirvaso) targets the persistent erythema of rosacea rather than inflammatory lesions. It is an alpha-2 adrenergic agonist that causes vasoconstriction, temporarily reducing facial redness.

It does not treat papules or pustules and is used for erythematotelangiectatic rosacea.

For moderate to severe papulopustular rosacea, oral antibiotics may be added to topical treatment.

Low-dose doxycycline (40 mg modified-release once daily, marketed as Efracea) is the preferred oral option, as it has anti-inflammatory effects at sub-antimicrobial doses and avoids the concerns about antibiotic resistance associated with conventional-dose antibiotics.

Oral metronidazole (200 mg to 400 mg twice daily for 8 to 12 weeks) is an alternative, though it carries a higher risk of systemic side effects including gastrointestinal disturbance and the disulfiram-like reaction with alcohol.

For severe or refractory rosacea, oral isotretinoin at low doses may be considered under specialist dermatological supervision.

Laser and intense pulsed light (IPL) therapies are effective for treating telangiectasia and persistent erythema that does not respond to topical or oral treatment.

How to use Rozex

Cleanse the affected areas of the face with a gentle, soap-free cleanser and pat dry.

Apply a thin layer of Rozex cream or gel to the affected areas twice daily, in the morning and evening.

Avoid the eyes, nostrils, mouth, and any broken or irritated skin. Allow the product to absorb for approximately 5 to 10 minutes before applying moisturiser, sunscreen, or cosmetics.

Treatment should continue for at least 3 to 4 months for an initial course. Your prescriber may recommend longer-term or intermittent use for maintenance.

Side effects of Rozex

Local skin reactions

The most common side effects are local skin reactions at the application site, including dryness, mild burning or stinging, irritation, and itching.

These are usually mild and improve within the first week of use.

If irritation is troublesome, try reducing to once-daily application temporarily or using a gentle moisturiser alongside Rozex.

Uncommon and rare effects

Allergic contact dermatitis is rare but possible. If you develop a new rash, blistering, or worsening redness after starting Rozex, stop using it and consult your prescriber.

Eye irritation may occur if the product is applied too close to the eyes. Systemic side effects are not expected due to negligible absorption.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Sun protection

Sun protection is a cornerstone of rosacea management regardless of treatment. UV exposure is one of the most common triggers for rosacea flares.

Use a broad-spectrum SPF 30 or higher sunscreen daily, even on cloudy days, and reapply every 2 hours during prolonged outdoor activity.

Choose a sunscreen formulated for sensitive skin. Avoid sunbeds and excessive sun exposure.

Rosacea trigger avoidance

Identifying and avoiding personal triggers can significantly reduce flare frequency.

Common triggers include sun exposure, wind, extreme temperatures, hot drinks, alcohol (particularly red wine), spicy food, vigorous exercise, emotional stress, and certain skincare products (fragrances, alcohol-containing toners, abrasive exfoliants).

Keeping a diary of flares and potential triggers can help identify your individual pattern.

Ocular rosacea

If you develop eye symptoms such as dryness, grittiness, burning, watering, redness of the eyelids, or blurred vision, consult your prescriber or optometrist.

Ocular rosacea can occur independently of or alongside skin rosacea and may require specific treatment, including lid hygiene, lubricant eye drops, and in some cases topical or oral antibiotics.

Untreated ocular rosacea can rarely lead to corneal complications.

When to seek further help

If your symptoms do not improve after 8 to 12 weeks of Rozex, or if they worsen, consult your prescriber.

A review of the diagnosis may be needed, as other conditions (such as acne, seborrhoeic dermatitis, lupus, or perioral dermatitis) can mimic rosacea.

Referral to a dermatologist may be appropriate for severe, atypical, or treatment-resistant rosacea. Rhinophyma (nose thickening) requires specialist surgical or laser treatment.

How to get Rozex in the UK

Rozex is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Generic metronidazole 0.75% cream and gel are also available and may be prescribed instead of the branded Rozex product.

Sources

• Rozex Cream, Summary of Product Characteristics (EMC)
• Metronidazole, British National Formulary (BNF)
• Rosacea, NICE CKS
• Rosacea, NHS
• Rosacea, British Association of Dermatologists (BAD)
• MHRA Yellow Card Scheme